Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy

Annovazzi, Pietro, Tomassini, Valentina ORCID: https://orcid.org/0000-0002-7368-6280, Bodini, Benedetta, Boffa, Laura, Calabrese, Massimiliano, Cocco, Eleonora, Cordioli, Cinzia, Luca, Giovanna, Frisullo, Giovanni, Gallo, Antonio, Malucchi, Simona, Paolicelli, Damiano, Pesci, Ilaria, Radaelli, Marta, Ragonese, Paolo, Roccatagliata, Luca, Tortorella, Carla, Vercellino, Marco, Zipoli, Valentina, Gasperini, Claudio, Rodegher, Mariaemma and Solaro, Claudio 2013. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences 34 (2) , pp. 197-203. 10.1007/s10072-012-0981-5

Full text not available from this repository.

Abstract

Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.

Item Type: Article
Date Type: Publication
Status: Published
Schools: MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Medicine
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Multiple sclerosis; Relapse; Corticosteroids; Survey; Management
Publisher: Springer Verlag
ISSN: 1590-1874
Last Modified: 21 Oct 2022 10:33
URI: https://orca.cardiff.ac.uk/id/eprint/40556

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item